Competing interests
Deniz
ONCOLOGY, FRANK
This clinical trial received financial support from Novartis. Steffen Koschmieder received research grant/funding from Geron, Janssen, AOP Pharma, and Novartis; received consulting fees from Pfizer, Incyte, Ariad, Novartis, AOP Pharma, Bristol Myers Squibb, Celgene, Geron, Janssen, CTI BioPharma, Roche, Bayer, and PharmaEssentia; received payment or honoraria from Novartis, BMS/Celgene, Pfizer; received travel/accommodation support from Alexion, Novartis, Bristol Myers Squibb, Incyte, AOP Pharma, CTI BioPharma, Pfizer, Celgene, Janssen, Geron, Roche, AbbVie, Sierra Oncology, and Karthos; had a patent issued for a BET inhibitor at RWTH Aachen University; participated on advisory boards for Pfizer, Incyte, Ariad, Novartis, AOP Pharma, BMS, Celgene, Geron, Janssen, CTI BioPharma, Roche, Bayer, Sierra Oncology, and PharmaEssentia. Susanne Isfort reports consultancy for Ariad, Novartis, Pfizer, Incyte; honoraria from Ariad, BMS, Pfizer, Incyte, and Novartis; other payments (e.g., travel support) by Alexion, Amgen, Hexal, Mundipharma, Novartis, Pfizer, and Roche. Dominik Wolf reports research funding, consultancy, and honoraria for Novartis, Pfizer, AOP, BMS/Celgene, and Incyte. Florian H. Heidel reports research funding from Novartis, CTI, Celgene/BMS and consultancy for Novartis, CTI, BMS/Celgene, AOP Pharma, Pfizer, Incyte. Andreas Hochhaus reports research support by Novartis, BMS, Incyte, Pfizer. Philippe Schafhausen reports consulting/advisory role/honoraria/travel and accommodation support from Alexion, AOP Orphan, Blueprint Medicines, BMS/Celgene, Merck Serono, MSD, Novartis, Pfizer, Roche, and Sobi. Martin Griesshammer reports consultancy, honoraria, or Speakers Bureau for Novartis, AOP Orphan, BMS, AbbVie, Pfizer, Roche, Janssen, Gilead, AstraZeneca, and Sierra. Uwe Platzbecker reports consultancy for Abbvie, Amgen, BMS, Novartis, Curis, and Pfizer. Konstanze Döhner reports consulting/advisory role/honoraria from AbbVie, Celgene/BMS, Novartis, CTI BioPharma Corp, and Roche. Philipp Jost reports a consulting or advisory role, received honoraria, research funding, and/or travel/accommodation expenses from Ariad, Abbvie, Bayer, Boehringer, Novartis, Pfizer, Servier, Roche, BMS and Celgene, Pierre Fabre, Janssen / Johnson&Johnson, MSD. Frank Stegelmann reports honoraria from and consultancy for AOP Pharma, BMS/Celgene, Incyte, Novartis, and Pfizer. Martina Crysandt received honoraria from Astra Zeneca and travel accommodation support from Pfizer, Incyte, and Novartis. Deniz Gezer reports advisory board activity for Amgen, Celgene, GSK, and Takeda; travel grants for Amgen, Celgene, Janssen/Cilag, and Takeda; and was invited speaker for Amgen, Celgene, BMS, GSK, and Takeda. Martin Hellmich received funding from the sponsor of the study (RWTH Aachen University) for statistical planning and analysis. Tim H. Brümmendorf served as a consultant for Janssen, Merck, Novartis, and Pfizer, received research funding from Novartis and Pfizer, received honoraria from Novartis and Pfizer, and received other support (e.g., travel support) from Janssen, Merck, Novartis, and Pfizer.